T-cell engager

Vir Biotechnology’s VIR-5500, a novel T-cell engager for advanced prostate cancer, showed promising safety and anti-tumor activity in Phase 1 trials. The therapy demonstrated significant PSA declines and objective responses in heavily pre-treated patients, with manageable side effects. This dual-targeting approach, utilizing PRO-XTEN® masking, aims for a differentiated therapeutic index, potentially offering a new option for patients with limited treatment choices.

.Molecular Partners (NASDAQ:MOLN) presented updated Phase 1/2a data for its tetra‑specific T‑cell engager MP0533 in relapsed/refractory AML at ASH 2025. Of 54 patients treated, 8 of 48 evaluable patients responded, including five composite complete responses and three morphologic leukemia‑free states. Densified, higher‑frequency dosing (cohorts 8‑9) was well tolerated and yielded markedly higher serum exposure, with responses concentrated in patients whose baseline marrow blasts were below 20 %. One cohort‑8 patient remains in remission for over a year; cohort 10 results are expected in 2026.